We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Broker Offer; Total Voting Rights

1 Nov 2022 15:56

RNS Number : 9682E
Deepverge PLC
01 November 2022
 

 

1 November 2022

 

DeepVerge PLC

 

("DeepVerge" or "Company")

 

Result of Broker Offer; Total Voting Rights

DeepVerge (AIM: DVRG), the environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, announces that, further to the announcement made on 27 October 2022, the Broker Offer, a facility to allow existing shareholders and other interested parties to participate in the Fundraise on the same terms to the Placing announced, has now closed having raised a gross amount of £0.815 million. The Company received interest of approximately £1 million which was scaled back to give priority to existing shareholders.

Subject to approval at the General Meeting to be held on 14 November 2022, a total of 40,750,000 ordinary shares of 0.1p nominal value each ("Broker Offer shares") will be allotted conditional only on Third Admission with investors at 2p per share, the same price as the Placing announced on 27 October 2022. Each Broker Offer Share will rank pari passu with existing Ordinary Shares. One Placing Warrant will be issued for every 4 Broker Offer Shares successfully subscribed.

Application will be made for admission of the 40,750,000 Broker Option Shares which will rank pari passu with existing Ordinary Shares to trading on AIM ("Third Admission"), with Third Admission expected to be on or around 16 November 2022.

Total Voting Rights

Following First Admission (which took place at 800am on 1 November 2022), the Company's issued share capital now consists of 252,662,334 shares with a nominal value of 0.1p each, with voting rights ("Ordinary Shares").

Following Second Admission (expected 15 November 2022, subject to the Resolutions being approved by Shareholders at the General Meeting scheduled for 14 November 2022 ("General Meeting")), the Company's issued share capital will consist of 387,662,334 Ordinary Shares.

Following Third Admission (expected 16 November 2022, subject to the Resolutions being approved by Shareholders at the General Meeting) the Company's issued share capital will consist of 760,456,378 Ordinary Shares.

The Company does not hold any Ordinary Shares in Treasury.

Therefore, following each respective Admission, the above figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Terms and definitions in this notification are as defined in the notification of 27 October 2022.

Dr Nigel Burton, Interim CEO, commented: "The Company and Board are grateful for the continued support of our shareholders in challenging markets. With a strengthened balance sheet, the Company can focus on leveraging its unique range of technologies to build on its strong customer base, accelerate the continued expansion of the business and deliver profitable growth and value for all our shareholders."

 

For further information, please contact:

Enquiries:

 

DeepVerge plc

Nigel Burton, Interim Chief Executive

+44 7785 234447

 

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited

(Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBUBDBDUGDGDB
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.